Welcome
to Tristan a Consortium for validating Translational
Imaging in Drug Safety Assessment
Our approach
We are using imaging techniques to improve drug safety analysis. This needs thorough validation of imaging procedures as “biomarkers”. This will help drug developers to bring new, safer drugs to the market and thereby enable doctors to treat their patients more effectively.
Learn more about the TRISTAN approachLiver transporter assessment
How we will help to improve detection of drug side effects that harm the liver.
Learn moreAssessment
of Diild
Improving imaging biomarkers to detect and understand potential drug side effects in the lung.
Learn moreBiologics-
PET
Improve analysis of bio-distribition of biologics by optimized PET imaging to aid reducing drug side effects.
Learn moreOur partners
Latest Posts
Symposium: MR Biomarkers of Toxicity
At the International Society for Magnetic Resonance in Medicine meeting 2019 in Montréal, TRISTAN participants co-organized a symposium on "MR biomarkers of toxicity"
Read More @ ISMRM websiteClinical ILD study is recruiting
TRISTAN's clinical study to assess imaging biomarkers to detect drug induced interstitial lung desease (DI-ILD) is recruiting patients from across the North of England. The TRISTAN-ILD study aims to assess the utility of MRI and CT methods in the identification and characterization of DI-ILD and ILD of other causes.
Read MoreGet in touch
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA
